Meeting
2017 ASCO Annual Meeting
Phase I study of the anti-HGF monoclonal antibody (mAb), ficlatuzumab, and cetuximab in cetuximab-resistant, recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC).
Authors
Julie E. Bauman
University of Arizona Cancer Center, Tucson, AZ
Julie E. Bauman , Umamaheswar Duvvuri , Robert L. Ferris , James Ohr , William E. Gooding , Seungwon Kim , Jonas Talmadge Johnson , Jennifer R. Grandis , Laura P. Stabile
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Head and Neck Cancer
Track
Head and Neck Cancer
Sub Track
Advanced/Metastatic Disease
Clinical Trial Registration Number
NCT02277197
Citation
J Clin Oncol 35, 2017 (suppl; abstr 6038)
DOI
10.1200/JCO.2017.35.15_suppl.6038
Abstract #
6038
Poster Bd #
26
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
A phase 1 study of concurrent cabozantinib and cetuximab in recurrent or metastatic head and neck squamous cell cancer.
First Author: Antoine Desilets
Poster
2020 ASCO Virtual Scientific Program
Randomized, phase II study of ficlatuzumab with or without cetuximab in patients with pan-refractory, recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC).
First Author: Julie E. Bauman
Poster
2011 ASCO Annual Meeting
Phase 1b study of ficlatuzumab (formerly AV-299), an anti-hepatocyte growth factor (HGF) monoclonal antibody (MAb) in combination with gefitinib (G) in Asian patients (pts) with NSCLC.
First Author: E. Tan
Poster
2023 ASCO Annual Meeting
Tazemetostat, a selective EZH2 inhibitor, with pembrolizumab as treatment of anti-PD-1 resistant head and neck squamous-cell carcinoma (HNSCC): A phase 1-2 trial.
First Author: Sidharth Puram